COVID-19 BLOOD PLASMA THERAPY OPTIONS ARE PROMISING : Healthcare, Digital Marketing and Market Access Strategy - John G. Baresky
Home
Adv-Mktg
Assisted Liv
Associations
Behavioral
Benefits
CROs
Data Firms
Dialysis
Government
GPOs
Health Sys
Insurance
Nursing Fac
Pharmacy
PBMs
Surgery Ctrs
Trade
Resources
Perspective
Contact

Clinical and Commercial Healthcare News Blog
Healthcare Medical Pharmaceutical Directory.com
Healthcare Industry Commentary
Market Trends...
  • 2020 sees new business models through ongoing mergers & acquisitions of healthcare provider and payer entities
  • Clinicians demanding more of digital technology ( artificial intelligence, imaging, clinical analytics, mobile, telemedicine, Internet-Of-Things (IoT) ) to enhance care despite its complexity and costs
  • Explore the diverse topics featured in this blog dedicated to healthcare and supported with fact-based insights



healthcare industry news and current events
Healthcare Medical Pharmaceutical Directory LinkedIn Page

COVID-19 BLOOD PLASMA THERAPY OPTIONS ARE PROMISING

by John G. Baresky on 05/28/20

Blood plasma therapy innovation driven by academic, healthcare and technology enterprises is confronting the COVID-19 challenge

Multiple clinical research initiatives are underway to learn more about the potential of blood plasma as a therapeutic approach to combat COVID-19. A pivotal assumption is a patient who has recovered from COVID-19 has produced antibodies to it. By using plasma from these patients and introducing it into patients who are critically ill from COVID-19, the plasma will fortify their systems with antibodies and provide them support to survive COVID-19 as their own immune systems develop COVID-19 antibodies.

Two clinical strategies are involved in COVID-19 blood plasma therapy

While there is differentiation between researchers and healthcare provider organizations exploring the attributes of COVID-19 blood plasma therapy, there are two approaches that presently have the most traction: 

  • One option is to transfer the blood plasma from the recovered COVID-19 patient to the ill COVID-19 patient by direct transfusion 
  • A second option being assessed is to collect the blood plasma from recovered patients and process it to create hyperimmune globulin that can be administered via IV transfusion to patients 

Timing is important. Medical professionals and researchers are most interested in the blood plasma from discharged COVID-19 patients within two months of their recovery as the presence of COVID-19 antibodies are likely at their peak.

Each COVID-19 blood plasma strategy has solid merit to further explore

The direct transfusion route is a simplistic approach however the hyperimmune globulin could treat a wider number of patients by producing more doses. Other hyperimmune globulin therapies that have been developed include:

  • Cytomegalovirus (CMV) (typically for use after bone marrow transplants and solid organ transplants)
  • Hepatitis B (HBV)
  • Rabies
  • RhoD (typically administered to prevent hemolytic disease of newborns or "HDN")
  • Tetanus
COVID-19 blood plasma solutions offer promise but more research is necessary to make the most of it

Wide support for further COVID-19 blood plasma therapy research stems from an array of medical professionals, healthcare provider organizations, information technology firms, government agencies and managed care organizations/payers.

These are some of the leaders providing funding, clinical, technical and other resources to drive insights and positive patient outcomes from blood plasma therapy solutions:
  • Anthem
  • Biomedical Advance Research And Development Authority (BARDA)
  • CSL Behring
  • Johns Hopkins University
  • LabCorp
  • Mayo Clinic
  • Microsoft
  • Takeda
  • University of Pittsburgh Medical Center (UPMC)
Resolving the COVID-19 pandemic demands more than one approach

The complex and dangerous attributes of COVID-19 requires it to be medically approached in more than one way. Not all treatment options may perform effectively in all patients and some solutions may be more easily developed and manufactured at scale to treat more patients sooner. 

Thankfully, there are numerous entities embracing the challenge and driving hard to develop novel solutions spanning oral antivirals, blood plasma-based therapies, monoclonal antibodies (mAbs), vaccines and other medicines to overcome the COVID-19 global pandemic.

 

Comments (0)


Leave a comment


Please use scroll bar to the right or finger swipe to view Healthcare Marketing blog updates...
Google Business Website Healthcare Medical Pharmaceutical Directory
Find Out How And Wherre To Get A COVID-19 Vaccine
...A healthcare industry business intelligence resource with marketing strategy insights for pharmaceutical and medical device manufacturers, healthcare provider organizations, medical software and technology enterprises, patient care service companies and management consulting firms spanning a global community of users from 50+ nations...